FDA Greenlights OKYO Pharma's Urcosimod for Pivotal Phase 3 Trial in Neuropathic Corneal Pain
OKYO sits 23% above its 52-week low of $1.42.
Summary
OKYO Pharma received positive FDA feedback from a Type D meeting for its lead candidate, urcosimod, for neuropathic corneal pain. This regulatory validation accelerates the drug directly into a global Phase 3 pivotal trial, with the potential for a single-trial registration strategy. For a clinical-stage biotech, this significantly de-risks the program and moves it closer to market for a condition with no FDA-approved therapies. The company plans to initiate the Phase 3 trial in the second half of this year.
At the time of this announcement, OKYO was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $89.9M. The 52-week trading range was $1.42 to $3.35. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.